To read the full story, subscribe or sign in.

Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion

April 21, 2008

A Phase II trial of the ACC-011 compound for Alzheimer's disease being developed by Elan Corp. plc and Wyeth Pharmaceuticals has been suspended due to a skin lesion observed in a single patient. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 7, 2025.

Pfizer’s PF-07853578 is candidate to treat MASH

BioWorld Science

The I148M mutation in the PNPLA3 gene, which encodes patatin-like phospholipase domain-containing protein 3, is known to confer risk of fatty liver, cirrhosis and...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

PFA non-inferior, even superior, to cryoablation for paroxysmal AF

BioWorld MedTech

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance...